Clinical Trial Update: A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

Clinical trial update for ARGX-119 in adults with amyotrophic lateral sclerosis (ALS), a Phase 2 safety and efficacy study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• ARGX-119

Snippet

Sponsor: argenx | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING